Send to

Choose Destination
See comment in PubMed Commons below
J Neuropsychiatry Clin Neurosci. 2008 Spring;20(2):178-84. doi: 10.1176/appi.neuropsych.20.2.178.

Double-blind randomized treatment of poststroke depression using nefiracetam.

Author information

Department of Psychiatry, The University of Iowa, 200 Hawkins Dr., Iowa City, IA 52242, USA.


In preliminary trials, nefiracetam, a gamma aminobutyric compound, enhanced blood flow and improved mood following stroke. Within 3 months following stroke with major depression, 159 patients were enrolled in a double-blind trial of nefiracetam or placebo. Repeated measures analysis of covariance failed to show a significant time-by-treatment interaction. Response rates were greater than 70% and remission rates were greater than 40% for nefiracetam and placebo. The top quintile of Hamilton Depression Rating Scale scores showed significant effect after 900 mg of nefiracetam versus 600 mg or placebo. Nefiracetam was not an effective treatment for poststroke depression but produced significant improvement in the most severely depressed patients.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center